Latest Conference Articles

February 15th 2013, 1:20pm

Genitourinary Cancers Symposium (ASCO GU)

The addition of dasatinib to standard therapy with docetaxel failed to improve survival and most other clinical endpoints in men with metastatic castration-resistant prostate cancer in the phase III READY trial.

February 15th 2013, 9:24am

Genitourinary Cancers Symposium (ASCO GU)

An updated interim analysis of the COU-AA-302 trial upholds the benefits of abiraterone acetate in mildly symptomatic or asymptomatic patients with progressive mCRPC untreated with prior chemotherapy.

February 15th 2013, 9:03am

Genitourinary Cancers Symposium (ASCO GU)

Use of corticosteroids had a negative impact on outcomes with enzalutamide treatment as well as placebo treatment in men with metastatic castrate resistant prostate cancer.

February 15th 2013, 8:08am

Genitourinary Cancers Symposium (ASCO GU)

William K. Oh, MD, from the Tisch Cancer Institute at Mount Sinai Medical Center, discusses the third interim analysis of the COU-AA-302 trial that examined abiraterone acetate before chemotherapy in mCRPC.

February 14th 2013, 4:05pm

Genitourinary Cancers Symposium (ASCO GU)

Abdenour Nabid, MD, from the Centre Hospitalier de Universitaire de Sherbrooke in Sherbrooke, Canada, discusses results of a phase III randomized study that compared 18 months of ADT to 36 in men with high-risk, localized prostate cancer.

February 14th 2013, 12:07pm

Genitourinary Cancers Symposium (ASCO GU)

Small renal masses identified in elderly patients can be safely managed by surveillance and maintain the same mortality risk as those who undergo surgery, suggesting that surgery could be avoided altogether in many patients.

February 14th 2013, 9:33am

Genitourinary Cancers Symposium (ASCO GU)

Deepak A. Kapoor, MD, president of the Large Urology Group Practice Association, discusses the implications of a large study looking at the detection of prostate cancer using prostate biopsies.

February 14th 2013, 8:29am

Genitourinary Cancers Symposium (ASCO GU)

Shortening the course of androgen blockade therapy from 36 months to 18 months when combined with radiation therapy does not appear to compromise outcomes in patients with high-risk prostate cancer

February 14th 2013, 6:48am

Genitourinary Cancers Symposium (ASCO GU)

A large, retrospective study has found that high-risk prostate cancer that can only be detected through PSA testing is more likely to occur among men over the age of 75 and in African Americans.

February 12th 2013, 7:09am

ASH Annual Meeting and Exposition

Francesco Lo-Coco, MD, Hematology, University Tor Vergata, discusses a new emerging treatment, arsenic trioxide, in acute promyelocytic leukemia.

January 28th 2013, 5:33pm

Gastrointestinal Cancers Symposium (ASCO GI)

Ghassan K. Abou-Alfa, MD, from Memorial Sloan-Kettering Cancer Center, discusses a study that examined the utility of doxorubicin-eluting beads in hepatic arterial embolization as a treatment for hepatocellular carcinoma.

January 28th 2013, 2:16pm

Gastrointestinal Cancers Symposium (ASCO GI)

The 2013 Gastrointestinal Cancers Symposium was held at the Moscone West Building, San Francisco, CA, from January 24-26.

January 28th 2013, 10:45am

Gastrointestinal Cancers Symposium (ASCO GI)

Adding nab-paclitaxel to gemcitabine improves survival compared with gemcitabine alone in patients with metastatic pancreatic cancer.

January 28th 2013, 10:10am

Gastrointestinal Cancers Symposium (ASCO GI)

Ramucirumab significantly extended overall survival as a second-line agent in patients with metastatic gastric or gastroesophageal junction adenocarcinoma that progressed on first-line therapy.

January 28th 2013, 9:56am

Gastrointestinal Cancers Symposium (ASCO GI)

Patients with metastatic colorectal cancer whose disease had progressed despite treatment with oxaliplatin experienced an improvement in survival by switching to a regimen of ziv-aflibercept plus FOLFIRI.

January 28th 2013, 9:01am

Gastrointestinal Cancers Symposium (ASCO GI)

Axel Grothey, MD, from the Mayo Clinic, Rochester, Minnesota, discusses the time course of adverse events following treatment with regorafenib, as observed in the CORRECT study.

January 25th 2013, 3:25pm

Gastrointestinal Cancers Symposium (ASCO GI)

Adjuvant chemotherapy with the oral fluoropyrimidine S-1 improved survival versus standard postoperative gemcitabine in Asian patients with pancreatic cancer, according to an interim analysis from a phase III trial conducted in Japan.

January 25th 2013, 1:10pm

Gastrointestinal Cancers Symposium (ASCO GI)

Ramesh K. Ramanathan, MD, from the Virginia G. Piper Cancer Center, discusses the phase III MPACT study that examined gemcitabine plus nab-paclitaxel in patients with metastatic adenocarcinoma of the pancreas.

January 25th 2013, 1:09pm

Gastrointestinal Cancers Symposium (ASCO GI)

William M. Grady, MD, from the Fred Hutchinson Cancer Research Center, discusses results from a study that examined the association of intrinsic subtypes of colorectal cancer with prognosis, chemotherapy response, and other factors.

January 25th 2013, 7:15am

Gastrointestinal Cancers Symposium (ASCO GI)

A simple blood draw could lead to life-prolonging adjustments in treatment for patients with pancreatic cancer, the authors of a study have found.